China’s Health Authorities Investigate Alleged Price Manipulation in Pharma Procurement Tenders
Chinese health regulators are delving into allegations of irregular pricing practices during the national volume-based...
Impact Therapeutics Boosts War Chest with $55.2 Million Series D+ Round for Cancer Drugs
Impact Therapeutics, a biopharmaceutical company based in China, has reportedly secured RMB 400 million (USD...
Beijing Sanbo Hospital and AGE Dr. Hospital Management Group Join Forces in Brain Disease Care
Beijing Sanbo Hospital Co., Ltd, a prominent healthcare provider in China, has entered into a...
Guangzhou LBP Earns NMPA Nod for HER2 Detection Reagent to Guide Breast Cancer Treatment
Guangzhou LBP Medicine Science & Technology Co., Ltd (SHA: 688393), a biopharmaceutical company based in...
Sichuan Biokin Gets NMPA Green Light for BL-B01D1 ADC in NSCLC Clinical Trial
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a leading biopharmaceutical company based in China, has...
Innovent Biologics’ Pemazyre Wins Macau Approval for Cholangiocarcinoma Treatment
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company in China, has received marketing approval...
Kintor Pharmaceutical’s GT20029 Meets Primary Endpoint in Phase II AGA Trial
Kintor Pharmaceutical Ltd (HKG: 9939), a clinical-stage biotechnology company, has announced that its Phase II...
Jiangsu Hengrui Pharmaceuticals Reports 7.26% Revenue Growth in 2023, Driven by Innovative Drugs
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has released...
China’s CDE Issues Guidelines for Pediatric Drug Labeling Updates
China’s Center for Drug Evaluation (CDE) has issued a notice outlining the “Detailed Rules for...
GSK’s Shingrix Vaccine Maintains High Efficacy for Over a Decade, Phase III Data Show
GlaxoSmithKline (GSK, LON: GSK, NYSE: GSK), the UK-based pharmaceutical giant, has this week released long-term...
AbbVie’s Rinvoq Meets Main Goal in Late-Stage Giant Cell Arteritis Trial
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, has announced that a late-stage clinical trial...
Chia Tai Tianqing’s Rovadicitinib Meets Main Goal in Myelofibrosis Trial, Eyes Market Filing
Chia Tai Tianqing, a renowned pharmaceutical company based in China, has declared that it has...
Shanghai Escugen and Anke Bio Partner to Develop ADC Products with EZWi-Fit Platform
Shanghai Escugen, a biopharmaceutical company based in China, has entered into a licensing and cooperation...
China’s CNIPA and USPTO Pledge to Deepen Intellectual Property Cooperation
Shen Changyu, Director of the China National Intellectual Property Administration (CNIPA), met with Kathi Vidal,...
Novartis’s Kesimpta Shows Sustained Efficacy in 6-Year Relapsing MS Study
Swiss pharmaceutical giant Novartis (NYSE: NVS) has this week unveiled six-year efficacy data for its...
Abbott Reports Q1 2024 Organic Sales Growth of 4.7%, Led by Pharmaceuticals and Devices
Abbott (NYSE: ABT), a global healthcare giant, has this week announced its financial results for...
CSPC Pharmaceutical Posts 1.7% Revenue Growth in 2023, Bolstered by Patent Medicine Sales
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has released...
ImmuneOnco Receives NMPA Approval for Phase III Clinical Trial of CD47 Inhibitor TIMDARPACEPT
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced that it has received approval from...
Shanghai Henlius Biotech Advances TIGIT-Targeting HLX53 to Phase II Clinical Trial for Hepatocellular Carcinoma
Shanghai Henlius Biotech Inc., (HKG: 2696), a biopharmaceutical company based in China, has received approval...
Amgen’s Tezspire Shows Promise in Phase IIa COPD Trial, Reduces Exacerbations
Amgen (NASDAQ: AMGN), a multinational biopharmaceutical company, has this week announced results from a Phase...